GlassScriptPhysician profile
Sherri Greif
NPI 1336371954
$4,523.04
in general payments reported to CMS, 2019-2025
27 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $759 · 2023: $1,213 · 2024: $1,118 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.64 |
| Education | $161.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $491.85 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $467.54 | 2021-2025 | Breztri, Lokelma |
| Abbott Laboratories | $327.87 | 2022-2024 | Infinity, Amplatzer Amulet |
| Abbvie INC. | $326.91 | 2021-2025 | |
| Lilly USA, LLC | $240.58 | 2022-2023 | Mounjaro |
| Acadia Pharmaceuticals INC | $216.11 | 2024-2025 | Nuplazid |
| Inari Medical, INC. | $166.80 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Microtransponder, INC. | $150.88 | 2023 | |
| Edwards Lifesciences Corporation | $142.90 | 2022 | |
| Inspire Medical Systems, INC. | $140.68 | 2023 | Inspire |
| Neurocrine Biosciences, INC. | $136.77 | 2025 | |
| Spr Therapeutics, INC | $135.27 | 2024 | Sprint Pns System |
| Ardelyx, INC. | $130.11 | 2025 | Ibsrela |
| Boston Scientific Corporation | $129.47 | 2022-2024 | Spyglass Discover |
| Alkermes, INC. | $129.38 | 2025 | Lybalvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $129.25 | 2024 | Arcalyst |
| Nevro Corp. | $122.25 | 2023 | Senza |
| Glaxosmithkline, LLC. | $121.92 | 2023 | Shingrix |
| Amgen INC. | $117.77 | 2024 | |
| Idorsia Pharmaceuticals US INC | $111.78 | 2023 | Quviviq |
| Verrica Pharmaceuticals INC. | $95.24 | 2024 | Ycanth |
| Hologic Sales and Service, LLC | $93.19 | 2024 | Aptima |
| Xeris Pharmaceuticals, INC. | $92.82 | 2023 | Gvoke Hypopen |
| Biosense Webster, INC. | $84.85 | 2025 | Carto 3 |
| Myovant Sciences INC. | $82.46 | 2022 | |
| Pfizer INC. | $69.50 | 2024 | |
| Scynexis, INC. | $68.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherri Greif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.